Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05568134
Other study ID # 22-020249
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date July 17, 2023
Est. completion date February 1, 2026

Study information

Verified date March 2024
Source Children's Hospital of Philadelphia
Contact Grey Baker
Phone (215)-590-3174
Email bakerg3@chop.edu
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Although early detection and treatment of cystic fibrosis-related diabetes (CFRD) can lead to significant clinical improvements and prolong life, rates of screening are poor likely due to the burdensome nature of oral glucose tolerance testing (OGTT). The investigators propose to assess the feasibility and accuracy of two screening tools, continuous glucose monitoring (CGM) and a home OGTT kit (GTT@home). If this pilot study reveals acceptable accuracy of either device, this study will allow for future studies exploring home-based OGTT screening.


Description:

The investigators hypothesize that there will be strong agreement between plasma glucose and glucose as measured by either CGM or GTT@home at three different timepoints during an OGTT: fasting, 1-hour, and 2-hours.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date February 1, 2026
Est. primary completion date February 1, 2025
Accepts healthy volunteers No
Gender All
Age group 10 Years and older
Eligibility Inclusion Criteria: - Diagnosis of cystic fibrosis - = 10 years of age - Fluency in written and spoken English as the GTT@Home is currently only available in English Exclusion Criteria: - Hospitalization or treatment with IV antibiotics or supraphysiologic glucocorticoids within 4 weeks - Major medical or psychiatric disorders other than CF - Use of medications known to impact the accuracy of the Dexcom G7 (hydroxyurea, >2g acetaminophen per day) - History of severe adhesive reactions that may lead to an inability to tolerate CGM wear

Study Design


Intervention

Diagnostic Test:
Oral glucose tolerance test
An oral glucose tolerance test will be completed. A fasting glucose will be measured. Participants will drink 1.75 g/kg of dextrose (up to a maximum of 75 grams) within 10 minutes. Glucose values will be measured at 1 hour and 2 hours.

Locations

Country Name City State
United States Children's Hospital of Philadelphia Philadelphia Pennsylvania

Sponsors (2)

Lead Sponsor Collaborator
Children's Hospital of Philadelphia Cystic Fibrosis Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Agreement between plasma glucose, CGM measured glucose using the Dexcom G7, and GTT@home glucose Differences in fasting glucose will be measured by the difference in mg/dl between plasma glucose, CGM measured glucose, and GTT@home measured glucose. Fasting glucose before OGTT
Primary Agreement between plasma glucose, CGM measured glucose using the Dexcom G7, and GTT@home glucose Differences in the 1 hour glucose during the OGTT will be measured by the difference in mg/dl between plasma glucose, CGM measured glucose, and GTT@home measured glucose. 1 hour mark in OGTT
Primary Agreement between plasma glucose, CGM measured glucose using the Dexcom G7, and GTT@home glucose Differences in the 2 hour glucose during the OGTT will be measured by the difference in mg/dl between plasma glucose, CGM measured glucose, and GTT@home measured glucose. 2 hour mark in OGTT
Secondary Agreement between the categorical diagnosis of normal glucose tolerance (NGT), impaired glucose tolerance (IGT), indeterminate glycemia (INDET), and CFRD as defined by plasma glucose, CGM glucose, and GTT@home glucose. Categorical diagnosis of glucose tolerance as measured by plasma glucose, CGM measured glucose using the Dexcom G7, and GTT@home glucose. Up to 2 hours
Secondary Difference between plasma glucose and CGM measured glucose after the fasting glucose Absolute differences between the glucose measurements will be measured in mg/dL Up to 20 minutes after the fasting glucose
Secondary Difference between plasma glucose and CGM measured glucose after the 1 hour mark during the OGTT. Absolute differences between the glucose measurements will be measured in mg/dL Up to 20 minutes after the 1 hour mark in the OGTT
Secondary Difference between plasma glucose and CGM measured glucose after the 2 hour mark during the OGTT. Absolute differences between the glucose measurements will be measured in mg/dL Up to 20 minutes after the 2 hour mark in the OGTT
Secondary The ability of untrained participants to successfully complete the GTT@home kit without any guidance from the research team Number of steps successfully completed as measured by the GTT@home instruction manual. Up to 2 hours
Secondary Impact of wearing a real-time CGM on participants' awareness of the importance of screening for and diagnosing CFRD. 60 minute semi-structured interviews will be conducted with participants. Transcripts will be analyzed using semantic content analysis Within 2 weeks after removal of the CGM
Secondary Perceived benefits and burdens of CGM use Participants will complete a CGM Benefits and Burdens survey, a 16-item measure used to assess perceptions of CGM technology in people with type 1 diabetes. Surveys may be completed on paper or online, as per the participant's preference. The survey is scored on a 5-point scale (agree/disagree scale). Within 2 weeks after removal of the CGM
See also
  Status Clinical Trial Phase
Completed NCT04696198 - Thoracic Mobility in Cystic Fibrosis Care N/A
Completed NCT00803205 - Study of Ataluren (PTC124™) in Cystic Fibrosis Phase 3
Terminated NCT04921332 - Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD N/A
Completed NCT03601637 - Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del Phase 3
Terminated NCT02769637 - Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)
Recruiting NCT06032273 - Lung Transplant READY CF 2: CARING CF Ancillary RCT N/A
Recruiting NCT06012084 - The Development and Evaluation of iCF-PWR for Healthy Siblings of Individuals With Cystic Fibrosis N/A
Recruiting NCT06030206 - Lung Transplant READY CF 2: A Multi-site RCT N/A
Recruiting NCT06088485 - The Effect of Bone Mineral Density in Patients With Adult Cystic Fibrosis
Recruiting NCT05392855 - Symptom Based Performance of Airway Clearance After Starting Highly Effective Modulators for Cystic Fibrosis (SPACE-CF) N/A
Recruiting NCT04056702 - Impact of Triple Combination CFTR Therapy on Sinus Disease.
Recruiting NCT04039087 - Sildenafil Exercise: Role of PDE5 Inhibition Phase 2/Phase 3
Completed NCT04038710 - Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.
Completed NCT04058548 - Clinical Utility of the 1-minute Sit to Stand Test as a Measure of Submaximal Exercise Tolerance in Patients With Cystic Fibrosis During Acute Pulmonary Exacerbation N/A
Completed NCT03637504 - Feasibility of a Mobile Medication Plan Application in CF Patient Care N/A
Recruiting NCT03506061 - Trikafta in Cystic Fibrosis Patients Phase 2
Completed NCT03566550 - Gut Imaging for Function & Transit in Cystic Fibrosis Study 1
Recruiting NCT04828382 - Prospective Study of Pregnancy in Women With Cystic Fibrosis
Completed NCT04568980 - Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
Recruiting NCT04010253 - Impact of Bronchial Drainage Technique by the Medical Device Simeox® on Respiratory Function and Symptoms in Adult Patients With Cystic Fibrosis N/A